Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors.
Anderson
R C
RC
Diabetes Department, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA.
Balestra
M
M
Bell
P A
PA
Deems
R O
RO
Fillers
W S
WS
Foley
J E
JE
Fraser
J D
JD
Mann
W R
WR
Rudin
M
M
Villhauer
E B
EB
D020155:3-Hydroxybutyric Acid; D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors*; D002478:Cells, Cultured; D015195:Drug Design; D005227:Fatty Acids / Q000378:metabolism; D006885:Hydroxybutyrates / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000145:classification / Q000494:pharmacology*; D008099:Liver / Q000201:enzymology; D063065:Organophosphonates / Q000737:chemistry / Q000494:pharmacology*; D010084:Oxidation-Reduction; D051381:Rats; D013329:Structure-Activity Relationship
D001786:Blood Glucose; D005227:Fatty Acids; D006885:Hydroxybutyrates; D007004:Hypoglycemic Agents; D063065:Organophosphonates; D002334:Carnitine O-Palmitoyltransferase; D020155:3-Hydroxybutyric Acid